Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application.
Clinical pharmacology
Mass spectrometry
ONC206
Ultra-HPLC
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
10 May 2022
10 May 2022
Historique:
received:
22
10
2021
revised:
28
01
2022
accepted:
20
02
2022
pubmed:
27
2
2022
medline:
6
4
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
ONC206 is an imipridone derivative that is being developed clinically as a single agent given orally in a first-in-human trial (NCT04541082). This ongoing clinical trial requires pharmacokinetic analysis of ONC206 to fully characterize its pharmacologic profile. There is currently no published bioanalytical method for ONC206 quantitation. To understand the clinical pharmacokinetics of ONC206, a sensitive yet simple uHPLC-MS/MS method for quantitation of ONC206 in human plasma was developed. Protein-precipitation allowed rapid and sensitive bioanalytical measurement of ONC206 in human plasma. A Phenomenex Kinetex C18 (50 ×2.1 mm, 1.3 µm, 100 Å) analytical column achieved symmetrical and sharp chromatography peaks of ONC206 and the internal standard, [
Identifiants
pubmed: 35219065
pii: S0731-7085(22)00106-6
doi: 10.1016/j.jpba.2022.114685
pmc: PMC8983588
mid: NIHMS1783709
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114685Subventions
Organisme : Intramural NIH HHS
ID : Z01 BC010548
Pays : United States
Informations de copyright
Published by Elsevier B.V.
Références
J Neurooncol. 2019 Oct;145(1):97-105
pubmed: 31456142
Sci Signal. 2016 Feb 16;9(415):ra17
pubmed: 26884599
J Anal Methods Chem. 2020 Feb 12;2020:9857636
pubmed: 32104611
Neuro Oncol. 2021 Apr 12;23(4):542-556
pubmed: 33336683
Oncotarget. 2014 Dec 30;5(24):12728-37
pubmed: 25587031
ACS Chem Biol. 2019 May 17;14(5):1020-1029
pubmed: 31021596
Sci Transl Med. 2013 Feb 6;5(171):171ra17
pubmed: 23390247
Oncotarget. 2016 Nov 8;7(45):74380-74392
pubmed: 27602582
Cell Cycle. 2017 Oct 2;16(19):1790-1799
pubmed: 28489985
Clin Chim Acta. 2014 Feb 15;429:143-6
pubmed: 24362229
Clin Cancer Res. 2018 Nov 1;24(21):5392-5406
pubmed: 30037819
Neoplasia. 2020 Dec;22(12):725-744
pubmed: 33142238
Mol Cancer. 2015 May 01;14:99
pubmed: 25927855
Front Oncol. 2020 Oct 20;10:577141
pubmed: 33194693